Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Ioana Kloos"'
Autor:
Nausheen Ahmed, Swetha Kambhampati, Mehdi Hamadani, Natalie Grover, Mazyar Shadman, Frederick Locke, James Gerson, Matthew J. Frank, L. Elizabeth Budde, Michael Wang, Zhen-Huan Hu, Ana Nunes, David Dalton, Ioana Kloos, Daniel Lee, Hairong Xu, Marcelo Pasquini, Alex F. Herrera
Publikováno v:
HemaSphere, Vol 7, p e43327c1 (2023)
Externí odkaz:
https://doaj.org/article/d985d6a9077240fe831b6d80cdd69b0d
Autor:
Esperanza M Algarín, Andrea Díaz-Tejedor, Pedro Mogollón, Susana Hernández-García, Luis A. Corchete, Laura San-Segundo, Montserrat Martín-Sánchez, Lorena González-Méndez, Marie Schoumacher, Sebastien Banquet, Laurence Kraus-Berthier, Ioana Kloos, Alix Derreal, Ensar Halilovic, Heiko Maacke, Norma C. Gutiérrez, María-Victoria Mateos, Teresa Paíno, Mercedes Garayoa, Enrique M. Ocio
Publikováno v:
Haematologica, Vol 105, Iss 3 (2020)
Externí odkaz:
https://doaj.org/article/512f9175196b4277b36f9d7dcf905aba
Autor:
Vincent Ribrag, Won Seog Kim, Reda Bouabdallah, Soon Thye Lim, Bertrand Coiffier, Arpad Illes, Bernard Lemieux, Martin J. S. Dyer, Fritz Offner, Zakia Felloussi, Ioana Kloos, Ying Luan, Remus Vezan, Thorsten Graef, Franck Morschhauser
Publikováno v:
Haematologica, Vol 102, Iss 5 (2017)
Histone deacetylase inhibitors are members of a class of epigenetic drugs that have proven activity in T-cell malignancies, but little is known about their efficacy in B-cell lymphomas. Abexinostat is an orally available hydroxamate-containing histon
Externí odkaz:
https://doaj.org/article/60433ef50a7d46828fefcd21b05bbe64
Autor:
Javier Munoz, Patrick M. Reagan, Andre H. Goy, David B. Miklos, Dan Zheng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Marie José Kersten, Michael Wang
Publikováno v:
Blood. 140:9320-9322
Autor:
Svenja Petersohn, Gilles Salles, Michael Wang, Jim Wu, Sally W. Wade, Claire L. Simons, Craig Bennison, Rubina Siddiqi, Weimin Peng, Ioana Kloos, Gab Castaigne, Georg Hess
Publikováno v:
Journal of Medical Economics. 25:730-740
The objective of this study is to estimate the cost-effectiveness of KTE-X19 versus standard of care (SoC) in the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) post Bruton tyrosine kinase inhibitor (BTKi) treatment f
Autor:
Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Patrick M. Reagan
Publikováno v:
Journal of Clinical Oncology, 94:02370. American Society of Clinical Oncology
Journal of clinical oncology, 94:02370. American Society of Clinical Oncology
Journal of Clinical Oncology
Journal of Clinical Oncology, 2023, 41 (3), pp.555-567. ⟨10.1200/JCO.21.02370⟩
Wang, M, Munoz, J, Goy, A, Locke, F L, Jacobson, C A, Hill, B T, Timmerman, J M, Holmes, H, Jaglowski, S, Flinn, I W, Mcsweeney, P A, Miklos, D B, Pagel, J M, Kersten, M J, Bouabdallah, K, Khanal, R, Topp, M S, Houot, R, Beitinjaneh, A, Peng, W, Fang, X, Shen, R R, Siddiqi, R, Kloos, I & Reagan, P M 2022, ' Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study ', Journal of Clinical Oncology, vol. 94, 02370 . https://doi.org/10.1200/JCO.21.02370
Journal of clinical oncology, 94:02370. American Society of Clinical Oncology
Journal of Clinical Oncology
Journal of Clinical Oncology, 2023, 41 (3), pp.555-567. ⟨10.1200/JCO.21.02370⟩
Wang, M, Munoz, J, Goy, A, Locke, F L, Jacobson, C A, Hill, B T, Timmerman, J M, Holmes, H, Jaglowski, S, Flinn, I W, Mcsweeney, P A, Miklos, D B, Pagel, J M, Kersten, M J, Bouabdallah, K, Khanal, R, Topp, M S, Houot, R, Beitinjaneh, A, Peng, W, Fang, X, Shen, R R, Siddiqi, R, Kloos, I & Reagan, P M 2022, ' Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study ', Journal of Clinical Oncology, vol. 94, 02370 . https://doi.org/10.1200/JCO.21.02370
PURPOSE Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47eb8b07d9f89522a14b8f20081cb6f6
https://research.vumc.nl/en/publications/4b65d325-cfe4-4902-889d-10f9ca14f692
https://research.vumc.nl/en/publications/4b65d325-cfe4-4902-889d-10f9ca14f692
Autor:
Houston Holmes, Ian W. Flinn, Patrick M. Reagan, Max S. Topp, John M. Timmerman, Weimin Peng, Michael Wang, Roch Houot, John M. Pagel, Amer Beitinjaneh, David B. Miklos, Peter A. McSweeney, Swaminathan Murugappan, Marie José Kersten, Andre Goy, Frederick L. Locke, Lianqing Zheng, Samantha Jaglowski, Javier Munoz, Noel Milpied, John M. Rossi, Caron A. Jacobson, Henry C.H. Fung, Ioana Kloos, Brian T. Hill
Publikováno v:
Blood. 136:20-22
Background: KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is currently being evaluated in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who received 1 - 5 prior therapies (including a Bruton tyr
Autor:
Loretta J. Nastoupil, Saurabh Dahiya, David Bernard Miklos, Patrick Michael Reagan, Matthew Ulrickson, A. Scott Jung, Ioana Kloos, Jinghui Dong, Justin Chou, Jodi Murakami, Katherine Rodriguez, Myrna Nahas
Publikováno v:
Journal of Clinical Oncology. 40:TPS7579-TPS7579
TPS7579 Background: One mechanism by which B-cell tumors can resist the effects of CD19-targeted CAR T-cell therapy is through CD19 antigen escape (Neelapu et al. ASH 2019). Recent analyses in large B-cell lymphoma (LBCL) demonstrated that approximat
Autor:
Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron Alyce Jacobson, Brian T Hill, John Timmerman, Houston Holmes, Ian W. Flinn, David Bernard Miklos, John M. Pagel, Marie José Kersten, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine Shen, Rubina Siddiqi, Ioana Kloos, Patrick Michael Reagan
Publikováno v:
Journal of Clinical Oncology. 40:7518-7518
7518 Background: Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL). In ZUMA-2, a 93% ob
Autor:
Patrick M. Reagan, Ioana Kloos, Lianqing Zheng, Allen Xue, Houston Holmes, Frederick L. Locke, John M. Rossi, Samantha Jaglowski, Caron A. Jacobson, Brian T. Hill, Adrian Bot, Michael L. Wang, Andre Goy, Xiang Fang, Weimin Peng, Javier Munoz
Publikováno v:
Transplantation and Cellular Therapy. 27:S341-S342